Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01014156
Other study ID # 03.123
Secondary ID
Status Completed
Phase Phase 4
First received November 13, 2009
Last updated November 13, 2009
Start date January 2004
Est. completion date June 2006

Study information

Verified date November 2009
Source Free University Medical Center
Contact n/a
Is FDA regulated No
Health authority Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study type Interventional

Clinical Trial Summary

You are admitted to hospital because of pulmonary embolism. You are treated with anticoagulants.

The investigators know that, despite this treatment, pulmonary embolism can be a threat especially if heart function is compromized.

The investigators investigate a well known study drug (epoprostenol) on top of regular treatment with anticoagulants, to see if heart function can be optimized


Description:

Pulmonary thromboembolism (PE) with circulatory and/or respiratory symptoms is associated with high morbidity and mortality. Acute pulmonary hypertension is the hallmark of severe PE, and is to be held responsible for the full spectrum of clinical manifestations and complications. Although it is common belief that only mechanical obstruction by thrombus mass causes this pulmonary hypertension, there is strong evidence indicating that pulmonary vasoconstriction contributes significantly to the rise in pulmonary vascular resistance.

Although all patients will receive anticoagulant treatment immediately after the diagnosis is established, morbidity and mortality are still disturbingly high when circulatory and/or respiratory symptoms accompany PE, or when hemodynamically stable PE patients have echocardiographic signs of acute right ventricle overload. There are no generally accepted guidelines for additional treatment options in these patients with moderate-to-severe PE. Thrombolytic therapy is recommended by many when hemodynamic symptoms are severe, but its effectiveness has never been proven in a controlled trial. In patients with moderate-to-large PE associated with echocardiographic signs of right ventricle overload, but who are still circulatory stable, mortality is increased, but thrombolytic therapy appears not to be beneficial.

Given the plausible role of pulmonary vasoconstriction in the pathogenesis of PE associated pulmonary hypertension, the potential benefit of pulmonary vasodilators is important.There is experimental evidence that antagonising pulmonary vasoconstriction by the administration of selective vasodilators may be beneficial in animals with PE. In addition, anecdotal evidence of a similar kind exists for humans with acute PE.

We hypothesise that in PE patients who have echocardiographic evidence of acute right ventricle overload, epoprostenol sodium (FlolanĀ®) results in partial or complete reversal of echocardiographic abnormalities, as well as in improvement in respiratory and circulatory symptoms and signs.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date June 2006
Est. primary completion date June 2006
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- acute (symptoms <24 hrs) with right ventricular dilatation (>30 mm end diastolic, systolic PAP > 50 mmHg,

- absence of right ventricular wall hypertrophy)

Exclusion Criteria:

- age below 18 years or above 70 years

- body mass index >35 kg/m2

- duration of symptoms >24 hours (since onset or acute increase in symptoms)

- severe circulatory shock (systemic blood pressure systolic <80 mmHg, or diastolic blood pressure <45 mmHg) or respiratory failure, requiring mechanical ventilation.

- patients who, in the opinion of the supervising physician, require thrombolytic therapy.

- severe pre-existent cardiopulmonary disease (heart failure, obstructive pulmonary disease, emphysema)

- atrial fibrillation

- refusal or inability to give informed consent

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
epoprostenol
titration up to 4 ng/kg/min

Locations

Country Name City State
Netherlands Free University Medical Center Amsterdam

Sponsors (1)

Lead Sponsor Collaborator
Free University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Right ventricular end diastolic diameter (ultrasound) 0, 2,5 4, 24 and 72 hours Yes
Secondary systolic pulmonary artery pressure (ultrasound) identical to primary measure Yes
See also
  Status Clinical Trial Phase
Completed NCT00519506 - A Phase II Study to Evaluate the Efficacy of ThromboView® in the Detection of Pulmonary Emboli Phase 2
Not yet recruiting NCT04110275 - Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA) Phase 2
Completed NCT05318092 - Evaluating the Safety and Efficacy of the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE for Treatment of Acute Pulmonary Embolism N/A
Not yet recruiting NCT05792397 - TwiFlow Thrombectomy Catheter sYstem for Acute Pulmonary Embolism (Twi-TYPE Study) N/A
Completed NCT01604538 - Italian Pulmonary Embolism Registry - IPER N/A
Completed NCT03631810 - Contemporary Clinical Management Of Acute Pulmonary Embolism
Recruiting NCT03504007 - Registry of Patients Prescribed Anticoagulation
Completed NCT01513759 - Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy Phase 3
Completed NCT03108833 - A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism Phase 2
Completed NCT04037423 - European Database on Catheter-directed Treatment of Pulmonary Embolism.
Not yet recruiting NCT06189313 - CLEANer Aspiration for Pulmonary Embolism N/A
Not yet recruiting NCT05469724 - Clinical Pulmonary Embolism
Recruiting NCT06038630 - 129Xe MRI Cardiopulmonary Phase 2
Recruiting NCT06192199 - The Diagnostic Value of APTT/Fibrinogen Ratio in Pulmonary Embolism
Recruiting NCT04757129 - Changes of Cardiopulmonary Function After Thrombolysis in Patients With Pulmonary Embolism
Completed NCT03966079 - Thrombolysis Endovascular Treatment of Pulmonary Embolism Phase 3
Recruiting NCT03916302 - Pulmonary Embolism WArsaw REgistry
Recruiting NCT06062329 - SYMPHONY-PE Study for Treatment of Pulmonary Embolism N/A
Not yet recruiting NCT04480892 - Fibrinolytic Deficit in Patients With Acute PE
Enrolling by invitation NCT04047784 - Pilot Study to Evaluate the Role of EBUS in the Diagnosis of Acute PE in Critically Ill Patients N/A